Compare PGY & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | GERN |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 900.1M |
| IPO Year | N/A | 1996 |
| Metric | PGY | GERN |
|---|---|---|
| Price | $12.41 | $1.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $34.50 | $3.00 |
| AVG Volume (30 Days) | 5.5M | ★ 13.9M |
| Earning Date | 02-09-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $1,301,360,000.00 | $183,403,000.00 |
| Revenue This Year | $18.57 | $146.80 |
| Revenue Next Year | $14.58 | $30.21 |
| P/E Ratio | $13.37 | ★ N/A |
| Revenue Growth | 26.07 | ★ 522.13 |
| 52 Week Low | $8.50 | $1.04 |
| 52 Week High | $44.99 | $2.84 |
| Indicator | PGY | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 24.69 | 69.05 |
| Support Level | $12.05 | $1.55 |
| Resistance Level | $15.51 | $1.69 |
| Average True Range (ATR) | 1.34 | 0.09 |
| MACD | -0.72 | 0.02 |
| Stochastic Oscillator | 4.03 | 90.05 |
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.